vimarsana.com
Home
Live Updates
CatalYm GmbH: CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination : vimarsana.com
CatalYm GmbH: CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
In an oral presentation at ESMO 2022, data from the GDFATHER-1 trial showed that treatment with visugromab and the anti-PD-1 inhibitor nivolumab resulted in excellent tolerability and significant anti-tumor
Related Keywords
Paris ,
France General ,
France ,
Spain ,
Germany ,
Switzerland ,
Kostenloser Wertpapierhandel ,
Catalym Gmb ,
Ignacio Melero Bermejo ,
Phil Lhuillier ,
Phil Lhuilier ,
International Coordinating Investigator Prof ,
Trophic Communications ,
European Society For Medical Oncology ,
European Society ,
Medical Oncology ,
International Coordinating Investigator ,
Universidad De Navarra ,
Eugen Leo ,
Chief Medical Officer ,
Phill Huillier ,
Chief Executive Officer ,
Clinical Benefit Rate ,
Ted Human Effector ,
Growth Differentiation ,
Phill Huilier ,
Stephanie May ,
Catalym ,
Mbh ,
Emonstrates ,
Linical ,
Efficacy ,
Tolerability ,
First ,
Human ,
Hase ,
Trial ,
Isugromab ,
Nivolumab ,
Combination ,
vimarsana.com © 2020. All Rights Reserved.